OSAKA, Japan, May 6, 2020 /PRNewswire-PRWeb/ -- Saisei Pharma
today announced plans to initiate an international clinical trial.
The decision is based on published preclinical evidence,
preliminary reports from independent studies and is supported by
data of the safety and efficacy of oral MAF in conditions that
require the involvement of macrophages as the front line defense in
innate immunity. Prior studies have indicated that oral MAF can
activate macrophage activity at least three-fold within a few
minutes after application. This outstanding phenomenon could play
an important role in deploying rapid innate immune response against
SARS-CoV-2. The MAF induced phagocytosis enhances antigen
processing and their presentation to effector lymphocytes, which is
critical in forming the adequate adaptive immune response and
synthesis specific antiviral antibodies [1-4]. Enhanced
phagocytosis of SARS-CoV-2 viral particles and quicker effective
innate and adaptive immune responses increase the probability of
the abortive or shorter infection course. In addition to reduced
viral load, MAF can downplay hyperactive proinflammatory response
causing respiratory failure.
''The efficient innate immune response against SARS-CoV-2 is
critical since there is no pre-existing immunity to exotic
coronaviruses in humans who were not exposed to it earlier. The
potent effect of Saisei Pharma MAF on phagocytosis is not
accompanied by clinical or biochemical signs of inflammation when
administered to humans. This means that our innate immunity can
fight off pathogens without causing inflammation and associated
respiratory deterioration" said immunologist Dr. Galyna Kutsyna,
MD/PhD.
"Saisei Pharma is taking a number of steps to address the urgent
need arising from the COVID-19 pandemic," said Dr. Toshio Inui, MD, Head Global Drug Development
and Chief Medical Officer. "The potential that oral MAF could lead
to faster recovery for COVID-19 patients with fewer requiring
intensive care and mechanical ventilation is encouraging and merits
further investigation. While oral MAF is very safe, its safety and
efficacy profile has not yet been established with regards to
COVID-19."
Given the global spread of the pandemic, and as plans for the
study are being finalized, Saisei Pharma also has set up an
international compassionate use program for eligible patients,
subject to local approvals. In addition, steps are taken to manage
the anticipated increase in COVID-19 related requests for oral MAF
without interrupting access for patients taking oral MAF for its
current indications. Saisei Pharma intends to join key industry
partners against COVID-19 to complement the array of available
therapy options. To support access, Saisei Pharma is committed to
keeping stable prices for its range of products that may help in
the treatment of COVID-19.
About Saisei Pharma oral MAF
Clinically active form of oral MAF is derived from
enzyme-treated dairy products. MAF resulted from decades-long
R&D activity by Saisei Pharma aimed at improving production
technology and ensure the product's higher activity and stability.
The final goal is to make oral MAF available globally for
conditions involving inadequate immune response due to macrophage
dysfunction and hyper immune-inflammatory disorders in adult and
pediatric patients. Saisei Pharma has filed a series of patents in
Japan, EU, USA, and worldwide which relate to the
technology, comprising the composition and method of production.
Oral MAF is available as a health food or immunomodulating
supplement in several countries, e.g., USA, Spain,
Lithuania, and Ukraine. The exact indication for oral MAF
varies by country. Additional worldwide regulatory filings are
underway in other countries. Information about Saisei Pharma is
available on the company website
http://www.saisei-pharma.co.jp.
Saisei Pharma Global Media Relations
Contact: Mr. Martin Mette
Email: contact-sp@saisei-pharma.co.jp
Tel: +81-90-8823-0885
References
1. Sumiya Y, Ishikawa M, Inoue T, Inui T, Kuchiike D, Kubo K, Uto
Y, Nishikata T. Macrophage activation mechanisms in human monocytic
cell line-derived macrophages. Anticancer Res 2015;35:4447-51.
2. Ishikawa M, Mashiba R, Kawakatsu K, Tran NK, Nishikata T.
(2018). A high-throughput quantitative assay system for macrophage
phagocytic activity. Macrophage 2018;5:e1627.
3. Uto Y, Kawai T, Sasaki T, Hamada K, Yamada H, Kuchiike D, Kubo
K, Inui T, Mette M, Tokunaga K, Hayakawa A, Go A, Oosaki T.
Degalactosylated/desialylated bovine colostrum induces macrophage
phagocytic activity independently of inflammatory cytokine
production. Anticancer Res 2015;35:4487-92.
4. Mohamad SB, Hori H, Nagasawa H, Usui K, Uto Y. Characterization
of human Gc protein-derived macrophage activation factor (GcMAF)
and its functional role in macrophage tumoricidal activity. Adv Exp
Med Biol. 2003;510:77‐82.
Disclaimer
This press release contains forward-looking statements regarding
potential marketing approvals, new indications or labeling for oral
MAF, regarding potential future revenues from such products,
regarding our plans to initiate a clinical trial to evaluate the
use of oral MAF in COVID-19 patients, or regarding the
international compassionate use program for eligible patients. You
should not place undue reliance on these statements. Such
forward-looking statements are based on our current beliefs and
expectations regarding future events and are subject to significant
known and unknown risks and uncertainties. Should one or more of
these risks or uncertainties materialize, or should underlying
assumptions prove incorrect, actual results may vary materially
from those set forth in the forward-looking statements. There is no
guarantee that oral MAF will be submitted or approved for sale or
for any additional indications or labeling in any market, or at any
predetermined time. Neither can there be any guarantee that we will
initiate the planned clinical trial in the expected time frame. Nor
can there be any guarantee that oral MAF will meet the primary or
secondary endpoints of the planned trial. Neither can there be any
guarantee that oral MAF will be commercially successful in the
future. Our expectations regarding Saisei products and the
international compassionate use program could be affected by, among
other things, the uncertainties inherent in research and
development, including clinical trial results and additional
analysis of existing clinical data; regulatory actions or delays or
government regulation generally; global trends toward health care
cost containment, including government, payor and general public
pricing and reimbursement pressures and requirements for increased
pricing transparency; our ability to obtain or maintain proprietary
intellectual property protection; prescribing preferences of
physicians and patients; general political, economic and business
conditions, including the effects of and efforts to mitigate
pandemic diseases such as COVID-19; safety, quality, data integrity
or manufacturing issues; potential or actual data security and data
privacy breaches, or disruptions of our information technology
systems, and other risks and factors. Saisei Pharma is providing
the information in this press release as of this date and does not
undertake any obligation to update forward-looking statements
contained in this press release as a result of new information,
future events or otherwise.
SOURCE Saisei Pharma